Tackling the Pricing Challenges for Advanced Therapies for Rare Diseases

Alice Valder Curran, partner with Hogan Lovells, discusses the challenges of value-based pricing for gene therapies, some of the pricing approaches developers are employing, and how the existing policy landscape complicates matters.